Letitia D. Jones

Letitia D. Jones

Auto-generated profile, based on publicly available information

Letitia D. Jones

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
Norbert PardiNorbert Pardi
Norbert Pardi
MHMichael J Hogan
Michael J Hogan
MNMartin S Naradikian
Martin S Naradikian
KPKaela Parkhouse
Kaela Parkhouse
DCDerek W Cain
Derek W Cain
DWDrew Weissman
Drew Weissman
T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this study, we characterize a recently developed vaccine platform, nucleoside-modified, purified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs), that induces high levels of Tfh and GC B cells. Intradermal vaccination with nucleoside-modified mRNA-LNPs encoding various viral surface antigens elicited polyfunctional, antigen-specific, CD4+ T cell responses and potent neutralizing antibody responses in mice and nonhuman primates. Importantly, the strong antigen-specific Tfh cell response and high numbers of GC B cells and plasma cells were associated with long-lived and high-affinity neutralizing antibodies and durable protection. Comparative studies demonstrated that nucleoside-modified mRNA-LNP vaccines outperformed adjuvanted protein and inactivated virus vaccines and pathogen infection. The incorporation of noninflammatory, modified nucleosides in the mRNA is required for the production of large amounts of antigen and for robust immune responses.

17 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LJLetitia D. Jones
Letitia D. Jones
JJJoseph W. Jackson
Joseph W. Jackson
SMSanjay Maggirwar
Sanjay Maggirwar
The number of HIV-1 positive individuals developing some form of HIV-associated neurocognitive disorder (HAND) is increasing. In these individuals, the integrity of the blood-brain barrier (BBB) is compromised due to an increase in exposure to pro-inflammatory mediators, viral proteins, and virus released from infected cells. It has been shown that soluble CD40L (sCD40L) is released upon platelet activation and is an important mediator of the pathogenesis of HAND but the underlying mechanisms are unclear, emphasizing the need of an effective animal model. Here, we have utilized a novel animal model in which wild-type (WT) mice were infected with EcoHIV; a derivative of HIV-1 that contains a substitution of envelope protein gp120 with that of gp80 derived from murine leukemia virus-1 (MuLV-1). As early as two-weeks post-infection, EcoHIV led to increased permeability of the BBB associated with decreased expression of tight junction protein claudin-5, in CD40L and platelet activation-dependent manner. Treatment with an antiplatelet drug, eptifibatide, in EcoHIV-infected mice normalized BBB function, sCD40L release and platelet activity, thus implicating platelet activation and platelet-derived CD40L in virally induced BBB dysfunction. Our results also validate and underscore the importance of EcoHIV infection mouse model as a tool to explore therapeutic targets for HAND.

1 March 2020 in Clinical Therapeutics
Verified
Journal Article
Open access
LJLetitia D. Jones
Letitia D. Jones
MMM. Anthony Moody
M. Anthony Moody
ATAmelia B. Thompson
Amelia B. Thompson
The field of HIV-1 vaccinology has evolved during the last 30 years from the first viral vector HIV gene insert constructs to vaccination regimens using a myriad of strategies. These strategies now include germline-targeting, lineage-based, and structure-guided immunogen design. This narrative review outlines the historical context of HIV vaccinology and subsequently highlights the scientific discoveries during the last 6 years that promise to propel the field forward. We conducted a search of 2 electronic databases, PubMed and EMBASE, for experimental studies that involved new HIV immunogen designs between 2013 and 2019. During the title and abstract reviews, publications were excluded if they were written in language other than English and/or were a letter to the editor, a commentary, or a conference-only presentation. We then used ClinicalTrials.gov to identify completed and ongoing clinical trials using these strategies. The HIV vaccinology field has undergone periods of significant growth during the last 3 decades. Findings elucidated in preclinical studies have revealed the importance of the interaction between the cellular and humoral immune system. As a result, several new rationally designed vaccine strategies have been developed and explored in the last 6 years, including native-like envelope trimers, nanoparticle, and mRNA vaccine design strategies among others. Several of these strategies have shown enough promise in animal models to progress toward first-in-human Phase I clinical trials. Rapid developments in preclinical and early-phase clinical studies suggest that a tolerable and effective HIV vaccine may be on the horizon.

2 March 2016 in Scientific Reports
Verified
Journal Article
Open access
FAFrancisco De Jesús Andino
Francisco De Jesús Andino
LJLetitia Jones
Letitia Jones
SMSanjay B. Maggirwar
Sanjay B. Maggirwar
Jacques RobertJacques Robert
Jacques Robert
While increasing evidence points to a key role of monocytes in amphibian host defenses, monocytes are also thought to be important in the dissemination and persistent infection caused by ranavirus. However, little is known about the fate of infected macrophages or if ranavirus exploits immune privileged organs, such as the brain, in order to establish a reservoir. The amphibian Xenopus laevis and Frog Virus 3 (FV3) were established as an experimental platform for investigating in vivo whether ranavirus could disseminate to the brain. Our data show that the FV3 infection alters the BBB integrity, possibly mediated by an inflammatory response, which leads to viral dissemination into the central nervous system in X. laevis tadpole but not adult. Furthermore, our data suggest that the macrophages play a major role in viral dissemination by carrying the virus into the neural tissues.

29 June 2017 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
RCRyan Connor
Ryan Connor
LJLetitia D. Jones
Letitia D. Jones
XQXing Qiu
Xing Qiu
JTJuilee Thakar
Juilee Thakar
SMSanjay Maggirwar
Sanjay Maggirwar
Leukocyte extravasation is a crucial feature of the normal immune response to disease and infection and is implicated in various pathologies during chronic inflammatory disease. P‐Selectin glycoprotein ligand‐1 (PSGL‐1) is critical for leukocyte extravasation; however, despite extensive study, it remains unclear how its expression is regulated, which in turn, impedes a more precise understanding of how its expression level affects transmigration. To investigate the regulation of PSGL‐1, 60 subjects, with or without HIV infection, were recruited and PSGL‐1 expression in monocytes was measured. PSGL‐1 was found to be up‐regulated on leukocytes from HIV‐infected individuals, and the physiologically relevant mediators soluble CD40 ligand (sCD40L) and glutamate were able to induce PSGL‐1 transcription in human monocytes ex vivo. HIV‐1 induced PSGL‐1 induction, and its dependence on CD40L was validated further by use of the mouse‐tropic HIV (EcoHIV) mouse model of HIV infection in C57BL/6 and CD40L knockout (KO) mice. To investigate crosstalk between the signaling cascades induced by CD40L and glutamate that lead to PSGL‐1 induction, a network‐based, discrete dynamic model was developed. The model reveals the MAPK pathway and oxidative stress as critical mediators of crosstalk between CD40L and glutamate‐induced pathways. Importantly, the model predicted induction of the c‐Myc transcription factor upon cotreatment, which was validated using transcriptomic data and pharmacologic inhibition of c‐Myc. This study suggests a novel systems serology approach for translational research and reveals a mechanism for PSGL‐1 transcriptional regulation, which might be leveraged to identify novel targets for therapeutic intervention.

6 June 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JJJoseph W. Jackson
Joseph W. Jackson
MSMeera V. Singh
Meera V. Singh
VSVir Bahadur Singh
Vir Bahadur Singh
LJLetitia D. Jones
Letitia D. Jones
GDGregory A. Davidson
Gregory A. Davidson
SMSanjay Maggirwar
Sanjay Maggirwar
Platelets play an essential role in hemostasis and wound healing by facilitating thrombus formation at sites of injury. Platelets also mediate inflammation and contain several pro-inflammatory molecules including cytokines and chemokines that mediate leukocyte recruitment and activation. Not surprisingly, platelet dysfunction is known to contribute to several inflammatory disorders. Antiplatelet therapies, such as aspirin, adenosine diphosphate (ADP) antagonists, glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, and anticoagulants such as warfarin, dampen platelet activity at the risk of unwarranted bleeding. Thus, the development of drugs that reduce platelet-mediated inflammation without interfering with thrombus formation is of importance to combat platelet-associated disorders. We have shown here for the first time that the tetracycline antibiotic, minocycline, administered to HIV-infected individuals reduces plasma levels of soluble CD40L and platelet factor 4 levels, host molecules predominately released by platelets. Minocycline reduced the activation of isolated platelets in the presence of the potent platelet activator, thrombin, as measured by ELISA and flow cytometry. Platelet degranulation was reduced upon exposure to minocycline as shown by mepacrine retention and flow cytometry. However, minocycline had no effect on spreading, aggregation, GPIIb/IIIa activation, or in vivo thrombus formation. Lastly, immunoblot analysis suggests that the antiplatelet activity of minocycline is likely mediated by inhibition of mixed lineage kinase 3 (MLK3)-p38 MAPK signaling axis and loss of p38 activity. Our findings provide a better understanding of platelet biology and a novel repurposing of an established antibiotic, minocycline, to specifically reduce platelet granule release without affecting thrombosis, which may yield insights in generating novel, specific antiplatelet therapies.